FILE:WAT/WAT-8K-20050127071431.txt.gz
EVENTS:	Results of Operations and Financial Condition	Financial Statements and Exhibits
TEXT:
ITEM: Results of Operations and Financial Condition
ITEM: Financial Statements and Exhibits
Table of Contents
Check the appropriate box below if the Form 8-K filing is intended to satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
Table of Contents
Item 2.02 Results of Operations and Financial Condition
     On January 27, 2005, Waters Corporation announced its results of operations for the quarter and year ended December 31, 2004. A copy of the related press release is attached hereto as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.
Item 9.01 Financial Statements and Exhibits
     Exhibit 99.1 Waters Corporation press release dated January 27, 2005 for the quarter and year ended December 31, 2004.
Table of Contents
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
For Immediate Release
Contact: Gene Cassis, Vice President of Investor Relations, 508-482-2349
Milford, Massachusetts, January 27, 2005  Waters Corporation (NYSE/WAT) reported today fourth quarter 2004 sales of $324.2 million, an increase of 18% over sales of $275.1 million in the fourth quarter of 2003. Foreign currency translation benefited revenue growth by approximately 4%. Quarterly earnings per diluted share (E.P.S.) were $0.58, compared to $0.47 for the fourth quarter in 2003. On a non-GAAP basis, excluding a write down for an investment in an unaffiliated company and for an impairment of a technology license, both recorded in the fourth quarter of 2004, and excluding a charge for expensed in-process research and development relating to an acquisition recorded in the fourth quarter of 2003, E.P.S. grew 29%, from $0.48 in the fourth quarter of 2003 to $0.62 in the fourth quarter of 2004.
For the full year, reported sales grew 15% from $958.2 million in 2003 to $1,104.5 million in 2004 while E.P.S. grew from $1.34 in 2003 to $1.82 in 2004. On a non-GAAP basis, including the adjustments noted above and in the attached reconciliation, E.P.S. grew 26% from $1.44 in 2003 to $1.81 in 2004.
Commenting on the quarter and the year, Douglas Berthiaume, Chairman, President and Chief Executive Officer said, " We had a strong fourth quarter as broad-based customer demand and successful new product launches drove top-line growth. The Waters Division benefited from sales of new products including ACQUITY UPLC and the QTof Premier while our TA Instruments Division finished the year with strong sales growth driven by continued robust customer demand. We are encouraged by the enthusiastic customer response to our newly introduced product platforms and are excited about our prospects in 2005."
As communicated in a prior press release, Waters Corporation will webcast its fourth quarter 2004 financial results conference call this morning, January 27, 2004 at 8:30 a.m. eastern time. To listen to the call, connect to www.waters.info , choose Investor Relations and click on the Live Webcast. A replay of the call will be available through February 2, 2005, similarly by webcast and also by phone at 402-280-9915.
Waters Corporation holds worldwide leading positions in three complementary analytical technologies  liquid chromatography, mass spectrometry and thermal analysis. These markets account for $4.5 - $5.0 billion of the overall $20 + billion analytical instrument market.
 
This release contains "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words, "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects", and similar expressions are intended to identify forward looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons including and without limitation: loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the demands of the Company's healthcare and pharmaceutical company customers, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company's products and foreign exchange fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-K for the year ended December 31, 2003, as filed with the Securities and Exchange Commission, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this press release and should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future.
 
 
The adjusted income per diluted share presented above is used by the management of the Company to measure operating performance with prior periods and is not in accordance with generally accepted accounting principles (GAAP). The above reconciliation identifies those items management has excluded as non-operational activities or transactions. Management feels these transactions are not indicative of understanding the ongoing operations of the business or its future outlook.
 


